AbbVie ABBV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion recommending granting conditional marketing authorization for the expanded use of its drug Tepkinly (epcoritamab) for treating relapsed/refractory follicular lymphoma (R/R FL). AbbVie is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with R/R FL after two or more prior therapies. The European Commission’s decision is expected later this year. Tepkinly, which is marketed as Epkinly in the United States, was approved by the FDA on an accelerated basis for the FL indication last week. Epkinly/Tepkinly was approved for relapsed-refractory third-line diffuse large B-cell lymphoma (DLBCL) in 2023. If approved for the FL indication, Tepkinly will become the first and only bispecific antibody conditionally approved as a monotherapy in the EU to treat both R/R FL and R/R DLBCL after two or more lines of prior therapy. Year to date, AbbVie’s stock has risen 10.7% compared with a rise of 21.1% for the industry. Zacks Investment Research Image Source: Zacks Investment Research FL is the most common form of indolent or slow-growing form of non-Hodgkin's lymphoma (NHL), while DLBCL is the most common form of aggressive or fast-growing form of NHL. The CHMP nod and FDA’s approval for the FL indication were based on data from the FL cohort of the phase I/II EPCORE NHL-1 study. Data from the study showed that patients who were treated with the drug achieved an overall response rate of 82%, including a complete response rate of 60%. Epkinly/Tepkinly has been developed by AbbVie in collaboration with Genmab GMAB as part of an oncology collaboration deal signed in 2020 to jointly develop and market three of the latter’s early-stage investigational bispecific antibody product candidates. Per the terms of the collaboration deal, AbbVie and Genmab share commercial responsibilities for epcoritamab in the United States and Japan. AbbVie is responsible for global commercialization. AbbVie’s share of profit from U.S. revenues of Epkinly and product revenues for Tepkinly from international markets were $27 million in the first quarter of 2024. AbbVie and Genmab are also evaluating Epkinly both as a monotherapy and as a combination regimen across lines of therapy in a range of hematologic malignancies. On Jun 28, the CHMP also recommended approving Merck’s MRK pulmonary arterial hypertension (PAH) drug Winrevair (sotatercept) in Europe. The decision of the European Commission is expected in the third quarter of 2024. If approved by the European Commission, Merck’s Winrevair will become the first activin signaling inhibitor therapy for PAH in Europe. Winrevair (sotatercept) was approved for pulmonary arterial hypertension in March 2024. Merck expects Winrevair to generate significant revenues over the long term. The CHMP also gave a positive opinion for the approval of J&J’s JNJ Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma (UC) in adult patients who have FGFR alterations. UC is the most common form of bladder cancer. The CHMP opinion was based on data from the THOR study. J&J’s Balversa is already approved for treating FGFR-altered locally-advanced or metastatic UC in the United States. J&J had submitted the marketing authorization seeking approval of Balversa in the EU in September last year. Zacks Rank AbbVie currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ):Free Stock Analysis Report Merck & Co., Inc. (MRK):Free Stock Analysis Report AbbVie Inc. (ABBV):Free Stock Analysis Report Genmab A/S Sponsored ADR (GMAB):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...